Expansion Therapeutics is a biotechnology company which is researching cures for genetic disorders. Myotonic dystrophy type 1 is one their researching. This genetic disorder is the most likely cause of an adult developing muscular dystrophy. So far they have raised $53.3 million to fund their research effort.
There are four main venture capital firms that are investing in Expansion Therapeutics. These are Novartis Venture Fund, 5AM Ventures, Sanofi Ventures, and Kleiner Perkins. To other firms also have a smaller stake in Expansion Therapeutics and these are RA Capital Management and Alexandria Venture Fund.
Research into muscular dystrophy has led to the conclusion that its symptoms are most likely due to a person’s RNA reaching toxic levels. When it reaches this toxic level in the person’s cells myotonic dystrophy type 1 is the result. Almost every system in their body becomes defective such as the central nervous system, muscles, hormonal system, as well as both the gastrointestinal and respiratory systems.
Myotonic dystrophy type 1 is a hereditary disease. When it is passed down the next generation it gets progressively worse for each generation that follows. To date there is no cure for muscular dystrophy which is what Expansion Therapeutics is trying to change.
5AM’s Ventures managing partner, Scott Rocklage, Ph.D., released a press statement when his firm invested in Expansion Therapeutics. He said that Matthew Disney, Ph.D., is the researcher upon whom Expansion Therapeutics is basing its research. He joined the team at Expansion Therapeutics and is using the knowledge that he as developed researching myotonic dystrophy type over the past 12 years. Dr. Disney has said that he expects positive results from his research in the not too distant future.
Scott Rocklage has been with 5AM ventures for 15 years. Prior to this he was an executive in the biotechnology industry where he led companies such as Cubist Pharmaceuticals as well as Nycomed Salutar. Earlier in his career he had a number of research and development positions for another biotechnology company, Catalytica. In addition to his work at 5AM Ventures he is also on the board for a number of other companies in the industry.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.